Funder
National Centre for Research and Development
Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Reference54 articles.
1. Corneal neovascularization: An anti-VEGF therapy review;Chang;Survey of Ophthalmology,2012
2. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization;Habot-Wilner;Acta Ophthalmologica,2010
3. Corneal penetration of topical and subconjunctival bevacizumab;Dastjerdi;Investigative Ophthalmology & Visual Science,2011
4. Bevacizumab in high-risk corneal transplantation: A pilot multicenter prospective randomized control trial;Dohlman;Ophthalmology,2022
5. T. Al-Debasi, A. Al-Bekairy, A. Al-Katheri, S. Al Harbi, M. Mansour, Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization, Saudi Journal of Ophthalmology 31 (2017) 99–105. https://doi.org/10.1016/j.sjopt.2017.02.008.